middle.news
Mesoblast Hits Recruitment Target for Pivotal Low Back Pain Trial
10:24am on Wednesday 29th of April, 2026 AEST
•
Healthcare
Read Story
Mesoblast Hits Recruitment Target for Pivotal Low Back Pain Trial
10:24am on Wednesday 29th of April, 2026 AEST
Key Points
Phase 3 trial enrols 300 patients with degenerative disc disease
Trial aims to confirm pain reduction and opioid cessation benefits
FDA RMAT designation enables priority regulatory review
Chronic low back pain market potential exceeds US$10 billion
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mesoblast (ASX:MSB)
OPEN ARTICLE